Charles River Laboratories (CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of $10.80.
- Revenue growth, reported 10.0% – 11.0%